A Five-Gene Model Predicts Clinical Outcome in ER+/PR+, Early-Stage Breast Cancers Treated with Adjuvant Tamoxifen

Hormones and Cancer

Volumn 2, Issue 5, 2011, Pages 261-271

  Kerr II, Daniel Alan ^a   Wittliff, James L ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Breast cancer; Disease free survival; Estrogen receptor; Gene expression; Overall survival; Progesterone receptor; Tamoxifen

Indexed keywords

CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR 4 JM A; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN BCL 2; RAS LIKE ESTROGEN REGULATED GROWTH INHIBITOR; RAS PROTEIN; TAMOXIFEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; FROZEN SECTION; GENE EXPRESSION PROFILING; GENETIC MODEL; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INVASIVE LOBULAR CARCINOMA; MEDULLARY CARCINOMA; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SURVIVAL RATE; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, PROGESTERONE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 80054023638     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-011-0080-8     Document Type: Article

References (45)

1. Cleator SJ, Ahamed E, Coombes RC, Palmieri C (2009) A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer 9(Suppl 1): S6-S17.
2. Fleisher M, Dnistrian AM, Sturgeon CM, Wittliff JL (2002) Practice guidelines and recommendations for use of tumor markers in the clinic. In: Diamandis DP, Fritsche HA, Lilja H, Chan DW, Schwartz MK (eds) Tumor markers: physiology, pathobiology, technology and clinical applications. AACC, Washington, DC, pp 33-63.
3. Sturgeon CM, Duffy MJ, Stenman UH et al (2008) National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54: e11-e79.
4. Wittliff JL, Pasic R, Bland KI (1998) Steroid and peptide hormone receptors: methods, quality control, and clinical use. In: Bland KI, Copeland EM (eds) The breast: comprehensive management of benign and malignant diseases. Saunders, Philadelphia, pp 458-498.
5. Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312.
6. Bezwoda WR, Esser JD, Dansey R, Kessel I, Lange M (1991) The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer 68: 867-872.
7. Dowsett M, Houghton J, Iden C et al (2006) Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17: 818-826.
8. Payne SJ, Bowen RL, Jones JL, Wells CA (2008) Predictive markers in breast cancer-the present. Histopathology 52: 82-90.
9. Wittliff JL (1984) Steroid-hormone receptors in breast cancer. Cancer 53: 630-643.
10. Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI (2005) Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 103: 2241-2251.
11. Ravdin PM, Green S, Dorr TM et al (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284-1291.
12. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21: 1973-1979.
13. Rakha EA, El-Sayed ME, Green AR et al (2007) Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25: 4772-4778.
14. Bryant J, Fisher B, Dignam J (2001) Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr 30: 56-61.
15. Clark GM, McGuire WL (1983) Progesterone receptors and human breast cancer. Breast Cancer Res Treat 3: 157-163.
16. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
17. Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26: 721-728.
18. Vendrell JA, Robertson KE, Ravel P et al (2008) A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Breast Cancer Res 10(5): R88.
19. Ma XJ, Wang W, Salunga R et al (2003) Gene expression associated with clinical outcome in breast cancer via laser capture microdissection. Breast Cancer Res Treat 82: A29.
20. Wittliff JL, Erlander MG (2002) Laser capture microdissection and its applications in genomics and proteomics. Methods Enzymol 356: 12-25.
21. Jin VX, Sun H, Pohar TT et al (2005) ERTargetDB: an integral information resource of transcription regulation of estrogen receptor target genes. J Mol Endocrinol 35(2): 225-230.
22. Fitzgibbons PL, Page DL, Weaver D et al (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 966-978.
23. Fisher B, Redmond C, Brown A et al (1981) Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305: 1-6.
24. Fisher B, Redmond C, Brown A et al (1983) Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1: 227-241.
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23: 9067-9072.
26. Schroeder A, Mueller O, Stocker S et al (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7: 3.
27. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
28. Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE (2008) The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res 68: 6387-6395.
29. Dupont WD (2002) Statistical modeling for biomedical researchers: a simple introduction to the analysis of complex data. Cambridge University Press, Cambridge.
30. Callagy GM, Webber MJ, Pharoah PD, Caldas C (2008) Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 8: 153.
31. Thomadaki H, Talieri M, Scorilas A (2007) Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett 247: 48-55.
32. Callagy GM, Pharoah PD, Pinder SE et al (2006) Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 12: 2468-2475.
33. DeSombre ER, Carbone PP, Jensen EV et al (1979) Special report. Steroid receptors in breast cancer. N Engl J Med 301: 1011-1012.
34. Kok M, Linn SC, van Laar RK et al (2009) Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 113(2): 275-283.
35. Kallio A, Zheng A, Dahllund J, Heiskanen KM, Harkonen P (2005) Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 10: 1395-1410.
36. Obrero M, Yu DV, Shapiro DJ (2002) Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem 277: 45695-45703.
37. Diel P, Smolnikar K, Michna H (1999) The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells. Breast Cancer Res Treat 58: 87-97.
38. Thiantanawat A, Long BJ, Brodie AM (2003) Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 63: 8037-8050.
39. Rio C, Buxbaum JD, Peschon JJ, Corfas G (2000) Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 275: 10379-10387.
40. Naresh A, Long W, Vidal GA et al (2006) The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 66: 6412-6420.
41. Zhu Y, Sullivan LL, Nair SS et al (2006) Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res 66: 7991-7998.
42. Finlin BS, Gau CL, Murphy GA et al (2001) RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. J Biol Chem 276: 42259-42267.
43. Sutherland DR, Keating A (1992) The CD34 antigen: structure, biology, and potential clinical applications. J Hematother 1: 115-129.
44. Bourdeau V, Deschenes J, Metivier R et al (2004) Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol 18: 1411-1427.
45. Dhakal HP, Naume B, Synnestvedt M et al (2008) Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination. Clin Cancer Res 14: 2341-2350.